+91-831-2422 668

Dr. Neeta Deshpande

MD,FRCP (Edin), PG Endo (Lond),
ASBP Cert Obesity (USA)


Dr Neeta Deshpande is a Diabetes and Obesity expert who has been in service of patients for more than 20 years. She graduated from JN Medical College, Belgaum and pursued post graduate studies (MD in Internal Medicine) from the same institute. After that, she has been certified for diabetes from the University of Newcastle, Australia, and for obesity from American Society of Bariatric Physicians (ASBP). She holds a post graduate diploma in Endocrinology from the Queen Mary University, London. She is also a Fellow of the Royal College of Physicians (FRCP), Edinburgh. She has undergone training and observerships in various institutes of repute such as Naomi Berrie Diabetes Centre (Columbia University, New York), Joslin Diabetes Centre (Boston, USA), Obesity department of University of Alberta, Edmonton, Canada.


Dr Neeta Deshpande is a crusader for lifestyle modification as a means of preventing and treating non-communicable diseases such as diabetes, pre-diabetes, obesity, fatty liver disease, etc.

She is an avid researcher and academician, having been active in the research field and published and presented papers at the national and international level in prestigious journals and conferences respectively. She has authored chapters in textbooks of diabetes and obesity, She is a prolific orator and is invited to address physicians and general practitioners across the country, delivering 25-30 lectures a year.


She has been interviewed and been on national television on issues related to diabetes and obesity.


Dr. Neeta Deshpande has been a strong force behind treating many patients overcome their diabetes and helped them get off their medication via her signature Lifestyle Program-Reversal of Diabetes She has also helped hundreds of patients achieve their goals of reducing weight by structuring customized plans.

5

Education

  • 1984-1989

    MBBS,Jawaharlal Nehru Medical College, Belgaum, Karnatak University

  • 1991-1994

    MD (Internal Medicine),Jawaharlal Nehru Medical College, Karnatak University

Postdoctoral training

  • 1998

    August – November 1998, training in Diabetology at S.L.Raheja Hospital, Mumbai,India of the All India Institute of Diabetes.

  • 2002

    Short course in Diabetes Care (TUNNDA), The University of Newcastle, Australia

  • 2008

    Training in Integrated Foot Care Services (InFoCeS), JIVAS, Bangalore, Sponsored byWorld Diabetes Foundation, Denmark, Jun, 2008

  • 2009

    Certificate of Advanced Training in Bariatric Medicine, Certified by American Board of Bariatric Medicine (now renamed ASBP)

  • 2012

    Certificate of Advanced Training in Obesity Medicine, Recertified by American Society of Bariatric Physicians (ASBP)

  • 2014

    PG Diploma Endocrinology, Queen Mary University, London

Training Observerships

  • 2000

    Joslin Diabetes Center, Boston, U. S. A

  • 2000

    Naomi Berrie Diabetes Center, Columbia University, New York

  • 2009

    Weight Wise Adult Bariatric Clinic in Royal Alexandria Hospital, University of Alberta,Edmonton, Canada, under Prof. Arya Sharma

Past Faculty Appointments and Professional Positions

  • 1994-2009

    Associate Professor and post graduate teacher in Internal Medicine, JawaharlalNehru Medical College, Belgaum, India

  • 1994-2009

    Consultant Physician and Diabetologist, KLE Hospital and Medical ResearchCentre, Belgaum, India

Current Faculty Appointments and Professional Positions

  • 1999 onwards

    Consultant Diabetologist, Belgaum Diabetes Centre, Belgaum, India

  • 2005 onwards

    Consultant Bariatric Physician, Weight Watch Weight Management Centre,Belgaum, India

  • 2010 onwards

    Professor and Head, Department of Medicine, Maratha Mandal Dental College,Belgaum, India (Rajiv Gandhi University of Health Sciences)

  • 2014 onwards

    Consultant Diabetologist, CHILDREN’S DIABETES CENTRE

  • 2015 onwards

    Associate Professor, Medicine, USM-KLE International Medical Programme, Belgaum, India

Leadership Positions

  • Appointed as Faculty Trainer by Public Health Foundation of India from 2011-2014 to train physicians in diabetes.

Professional Societies

  • a.  API – Association of Physicians of India.
    b.  IMA – Indian Medical Association.
    c.  RSSDI – Research Society for Study of Diabetes in India.
    d.  DFSI – Diabetic Foot Society of India.
    e.  DIPSI – Diabetes in Pregnancy Study in India.
    f.  The Endocrine society(USA).
    g.  AACE – Amerrican Association of Clinical Endocrinologists.

Honours , Prizes, Positions in Academic Bodies

  • 1985

    Secured 1st class at the 1st MBBS examination

  • 1987

    Secured 1st class at the 2nd MBBS examination

  • 1988

    1988 Secured 1st class at the 3rd MBBS examination

  • 2003

    Best Paper Award for the study titled “Correlation of post-prandial triglycerides and Carotid Intima-media thickness in type 2 diabetic patients” at The Research Society for the study of Diabetes in India National Annual Conference

  • 2007

    Felicitated by Chief Minister of Karnataka State, India for work done in Podiatry

  • 2007-2009

    Elected as Vice Chairman of Research Society for the study of diabetes in India( RSSDI), Karnataka Chapter for the year 2007-2008 and 2008-2009

  • 2009

    Elected as Chairman, RSSDI, Karnataka Chapter, for the year 2009-2010

  • 2015-2016

    IMA Belgaum CME Chairperson for the year

  • 2016

    Conferred the Oration Lecture “KRSSDI Oration” by Karnataka Chapter of RSSDI (Research Society for Study of Diabetes in India) and delivered the Oration on “Lifestyle Management-anunderrated tool in diabetes andobesity”.

  • 2016

    2016 Conferred the FRCP (Edinburgh)

Research Past

  • PRINCIPAL INVESTIGATOR from the year 2006, for more than 45 global clinical trials spanning Phase 1 to Phase 4, in diabetes, obesity, cardiac prevention trials and diabetic foot, some of which are listed below in the published articles, in the Collaborator List. Some of the recently completed trials are:

  • HOPE 3 – Principal Investigator

    A large, simple multicentre, international randomized placebo-controlled trial utilizing a 2 x 2 factorial design and evaluating cholesterol modification with rosuvastatin vs. placebo, blood pressure lowering with candesartan/HCT vs. placebo and combined treatment with rosuvastatin and candesartan/HCT vs. placebo on major vascular events Acronym: HOPE-3 (Heart Outcomes Prevention Evaluation. Currently in the phase of passive follow up.

    Sponsor - Population Health Research Institute, McMaster University Hamilton General Hospital237,Barton St

  • CAROLINA - Principal Investigator. Recently completed

    A multicentre, international, randomised, parallel group, double blind study to evaluate Cardiovascular safety of linagliptin versus glimepiride in patients with Type 2 Diabetes Mellitus at high cardiovascular risk."

    Sponsor - Boehringer Ingelheim Pharmaceuticals

  • CANVAS – Principal Investigator

    A Randomized, global, multicenter, Double-Blind, Parallel, placebo-Controlled Study to evaluate the Effects of JNJ- 28431754 on Cardiovascular Outcomes in Adult Subjects With Type 2 Diabetes Mellitus.

    Sponsor – Johnson and Johnson

Research Ongoing

  • 2012 - TIPS 3 – Principal Investigator

    A randomized double-blind placebo-controlled trial for evaluation of a polycap, low dose aspirin and vitamin D supplementation in primary prevention-The International Polycap study 3 (TIPS 3) Sponsors - Cadila Pharmaceuticals Limited , Wellcome Trust

  • 2016 – REVERSAL OF DIABETES and OBESITY PROGRAM

    A lifestyle modification program undertaken by Belgaum Diabetes Centre to reverse or remit type 2 diabetes and obesity.

Publications - Journals

  • Diabetes in Pregnancy, Neeta Deshpande, Journal of South Asian Federation of Obstetrics and Gynaecology 2010, Vol 2, Number 1, Pages 1-5

  • Hypoglycemia in type 2 diabetes: Standpoint of an experts' committee (India hypoglycemia study group) Indian J Endocrinol Metab.Year : 2012 | Volume : 16 | Issue : 6 | Page : 894-898 Mohan Viswanathan1, Shashank R Joshi2, Anil Bhansali3, Mohan Badgandi4, Subhankar Chowdhury5, Neeta Deshpande6, Shreerang Godbole7, K Kannan8, Surender Kumar9, RV Jayakumar10, Tiny Nair11, Prashant Narang12, Anant =Nigam13=, Mihir Saikia14=, Bipin Sethi15=, MA Shekar16=, Vikram=, SS Srikanta17=, KK -Tripathi18-, Vijay Viswanathan19-, SK Wangnoo20

  • Eight cases of bladder cancer in pioglitazone users from India. Unnikrishnan R, Sundramoorthy C, Deshpande N, Sarvothaman R, Sahay RK, Mehtalia S, Venkatraman JV, Mohan V. J Assoc Physicians India. 2012 Dec;60:66.

  • Clinical experience with insulin detemir, biphasic insulin aspart and insulin aspart in people with type 2 diabetes: Results from the Karnataka cohort of the A1chieve study.
    Indian J Endocrinol Metab. 2013 Nov;17(Suppl 2):S552-6. doi: 10.4103/2230-8210.122132. Deshpande N1, Ayyar V2, Channabasavaiah R3, Shetty R3, Behl A4.

  • Weight adds weight to declining quality of life in diabetes. Aravind SR1, Deshpande N. Curr Med Res Opin. 2014 Jul;30(7):1275-8. doi: 10.1185/03007995.2014.901944. Epub 2014 Mar 26.

  • Phenotypic severity of homozygous GCK mutations causing neonatal or childhood-onset diabetes is primarily mediated through effects on protein stability. Raimondo A1, Chakera AJ2, Thomsen SK1, Colclough K3, Barrett A1, De Franco E4, Chatelas A1, =Demirbilek H5=, Akcay T6=, Alawneh H7=; The International NDM Consortium, Flanagan SE4=, -Van De Bunt M1-, Hattersley AT2-, Gloyn AL8-, Ellard S9-; The International NDM Consortium. Collaborators (22) Abduljabbar MA, Al-Zyoud M, Aman S, Bath L, De P, Deshpande N, Durmaz E, Eickmeier F, Elbarbary NS, Fillion M, Jagadeesh SM, Kershaw-M, Khan WI, Mlynarski W, Noyes K, Peters CJ, Shaw N, Tiron I, Turkkahraman D, Turner-L, Eltonbary KY, Yuksel B. Hum Mol Genet. 2014 Dec 15;23(24):6432-40

  • Madhu S V, Saboo B, Makkar M B, Reddy G C, Jana J, Panda J K, Singh J, Shetty N, Rao PV, Chawla R, Sahay R K, Sosale A, Banarjee S, Bajaj S, Kumar V, Panikar V,Munichoodappa C, Mohan V, Kumar K M P, Ayyer V, Unnikrishnan R, Reddy S, Sosale B, Mohan A, Chowdary S, Tandon N, Ramachandran A, Bachani D, Aggarwal A, Misra A, Vikram N, Ghosh S, Deshpande N, Sharma J K, Das A K, Sahay B K, Bantwal G, Unnikrishnan A G, Rao S, Joshi S,Vishwanathan V, Bhoraskar A, Negalur V, Chopra V, =Gupta A, Aggarwal S, Sheshadri K, Dharmalingam M, Sanyal D, Mittal V, Vidyasagar S, Singh S K, Jaggi S, Das S, Kalra S, Julka S, Gupta Y, Punyani H on behalf of the Guideline Development Group. RSSDI Clinical Practice Recommendations for Management of Type 2 Diabetes Mellitus, 2015, Int J Diabetes Dev Ctries Oct 2015;35:S1-S71.

  • A Multicenter Real-Life Study on the Effect of Flash Glucose Monitoring on Glycemic Control in Patients with Type 1 and Type 2 Diabetes. Ranjit Mohan Anjana, MD, PhD, 1  Jothydev Kesavadev, MD, 2  Deshpande Neeta, MD, 3  Mangesh Tiwaskar, MD, 4  Rajendra Pradeepa, MSc, PhD, 1,2  Saravanan Jebarani, EMBA, 1  Suresh Thangamani, MSc, 1  Nadiminty Ganapathi Sastry, MBBS, Dip.Diab, 1  Srivastava Brijendra Kumar, MBBS, F.Diab, 1  Muthu Ramu, MD, F.Diab, 1  Pokal Prasanna Kumar Gupta, MBBS, F.Diab, 1  Jayaprakash Vignesh, MBBS, F.Diab, 1 Sundramoorthy Chandru, MBBS, F.Diab, 1  Sengottuvel Kayalvizhi, MBBS, F.Diab, 1  Padoor Sethuraman Jagdish, MBBS, F.Diab, 1  Subash Chandra Bose Uthra, MBBS, F.Diab, 1  Munawar Lovelena, MBBS, F.Diab, 1  Sah Jyoti, MD, 1  Sengodan Suguna Priya, MBBS, DFM, 1  Alagarsamy Kannan, MBBS, F.Diab, 1  Viswanathan Mohan, MD, DSc, 1  and Ranjit Unnikrishnan, MD 1 Diabetes Technology & Therapeutics. September 2017, Vol. 19, No. 9: 533-540

In the Collaborator/Investigator Listing

  • Effects of a polypill (Polycap) on risk factors in middle-aged individuals without cardiovascular disease (TIPS): a phase II, double-blind, randomised trial The Indian Polycap Study (TIPS) Lancet Volume 373, No. 9672, p1341–1351, 18 April 2009.

  • Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med. 2013 Oct 3;369(14):1327-35.

  • Empagliflozin monotherapy with sitagliptin as an active comparator in patients with -type 2 diabetes: a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Diabetes Endocrinol. 2013 Nov;1(3):208-19.

  • Effect of aleglitazar on cardiovascular outcomes after acute coronary syndrome in -patients with type 2 diabetes mellitus: the AleCardio randomized clinical trial. JAMA. 2014 Apr 16;311(15):1515-25.

  • A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management (SCALE Study) N Engl J Med 2015; 373:11-22.

  • Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome (ELIXA) N Engl J Med 2015; 373:2247-2257.

Publications – Book Chapters

  • 2000

    Hyper Androgenism in Adolescence in “Adolescence- Obstetrics and Gynaecology in Perspective” published by Orient Longman

  • 2003

    Pathogenesis of Insulin Resistance-Newer Concepts in “Newer Horizons in type 2 diabetes”

  • 2004

    Problems of Diabetes Care In Rural Patients –Do We Have The Solutions? In “Type 2 diabetes – Urban-Rural”

  • 2005

    Patient Education in Type 2 Diabetes in “Type 2 Diabetes in Elderly”.

  • 2006

    Insulin Resistance And Dyslipidemia in “Type 2 Diabetes and The Role of Insulin Resistance”.

  • 2010

    Prediabetes:To Treat or Not? In “Controversies in Type 2 Diabetes”

  • 2016

    Glucagon like peptide 1 Analogs for Obesity Management in “RSSDI Diabetes Update 2016”

  • Appointed as Section Editor (Section on Diabesity) “Sadikot’s Textbook of Diabetes” to be released in December 2017. Book released at IDF

  • Contributed chapter titled “Malignancy and Diabetes” to the RSSDI Textbook of diabetes.

  • Chapter in RSSDI Diabetes Update 2018 “Obesity Management:Surgical knife or Drugs and Lifestyle?”.

  • Chapter in API Update 2019 “Reversal of Diabetes”

Abstracts

  • “Study of Pancreatic Diabetes”, Joint Annual Conference of API and CSI, Karnataka Chapter, June 1994, Mysore.

  • “Association of microalbuminuria and dyslipidemia in Type 2 diabetes” at the IXth National Congress on Diabetes Mellitus, Diabetic Association of India, November1998, Mumbai

  • Overall Obesity and Waist Hip Ratios in Type 2 Diabetes”, 55th Joint Annual Conference APICON 2000, Jan 2000, Jaipur.

  • “Correlation of post-prandial triglycerides and Carotid Intima-media thickness in type 2 diabetic patients” – RSSDI National Meet 2003, Jaipur.

  • “Combination Therapy for control of diabetes mellitus” was presented in November 2006 in the national RSSDI Conference.

  • “Stratification of high risk feet in type 2 diabetes” was presented at DFSI National Meet, Mumbai, October, 2006

  • “Assessment and Correlation of diabetes related ASK (Attitudes, Skills, and Knowledge)to glycemic control in a diabetic population” was presented in the national conference organized by the Research Society for Study of Diabetes in India, Calcutta , November 2007.

  • “Correlation of serum high sensitivity C – reactive protein level to various grades of obesity in an Asian population” was presented in the European Congress of obesity, Geneva, Switzerland in May 2008.

  • “Comparison of serum High Sensitivity C – Reactive Protein (HSCRP) levels in Normal Weight Obese individuals with Non-Obese individuals”, was presented in the 2nd World Congress on Controversies to Consensus in Diabetes, Obesity and Hypertension (CODHy),Barcelona, Spain in October 2008.

  • “Foot abnormalities in diabetics – Prevalence and predictors in an Asian population.”was presented in the 2nd World Congress on Controversies to Consensus in Diabetes, Obesity and Hypertension (CODHy) ,Barcelona, Spain in October 2008.

  • “Body Fat Percentage and Normal Weight Obesity in patients of type 2 diabetes in an Asian population” was presented in the 2nd World Congress on Controversies to Consensus in Diabetes, Obesity and Hypertension (CODHy) ,Barcelona, Spain in October 2008.

  • “Comparison of insulin resistance and other metabolic abnormalities in Normal Weight Obese with Non-Obese type 2 diabetic individuals” was presented in the 2nd World Congress on Controversies to Consensus in Diabetes, Obesity and Hypertension (CODHy),Barcelona, Spain in October 2008.

  • “Combination therapy for control of diabetes – does insulin therapy really matter?” was presented in the 2nd World Congress on Controversies to Consensus in Diabetes, Obesity and Hypertension (CODHy) ,Barcelona, Spain in October 2008.

  • “Inflammation and Insulin resistance in an Asian Diabetic Cohort”, 2009, was presented in the National Diabetic Conference organized by the Research Society for Study of Diabetes in India, Ahmedabad in November 2009.

  • “Comparison of diabetic profile and anthropometry amongst individuals having low adiponectin levels with those having normal to high levels” in 2009, presented at the 27th Annual scientific meeting of the American Obesity Society held in Washington DC, U.S.A in October 2009.

  • “Gender and age related differences in body composition and prevalence of obesity in a semi urban Asian-Indian population” was presented in the 20th World Diabetes Congressof the International diabetes Federation , Montreal, Canada in October 2009.

  • “Insulin resistance and its relationship with age in an Asian diabetic cohort” ” was presented in the 20th World Diabetes Congress of the International diabetes Federation,Montreal, Canada in October 2009.

  • “Effect of dietary carbohydrate to protein ratio on body weight, body composition and glycemic control in Type 2 diabetes” ” was presented in the 20th World Diabetes Congress of the International diabetes Federation , Montreal, Canada in October 2009.

  • “Plasma adiponectin levels in normal weight obese, non-obese and obese in Indian type2 diabetic subjects” ” was presented in the 20th World Diabetes Congress of the International diabetes Federation, Montreal, Canada in October 2009.

  • Study sponsored by Research Society for Study of Diabetes in India, entitled:
    “Comparison of plasma adiponectin levels between normal weight and overweight type-2 diabetic individuals – a case control study.

Other activities

  • Selected by Rotary International for Group Study Exchange Program as a Cultural Ambassador to the U. S. A. for April 2000.

  • Other interests include vocal music, cycling, literature and arts.